Abstract:Summary Background COVID-19 vaccines used in humans are highly effective in limiting disease and death caused by the SARS-CoV-2 virus, yet improved vaccines that provide greater protection at mucosal surfaces, which could reduce break-through infections and subsequent transmission, are still needed. Methods Here we tested an intranasal (I.N.) vaccination with the receptor binding domain of Spike antigen of SARS-CoV-2 (S-RBD) in combination with the mucosal adjuvant mastoparan-7 compared with the sub-cutaneous (S.C.) route, adjuvanted by either M7 or the gold-standard adjuvant, alum, in mice, for immunological read-outs. The same formulation delivered I.N. or S.C. was tested in hamsters to assess efficacy. Findings I.N. vaccination improved systemic T cell responses compared to an equivalent dose of antigen delivered S.C. and T cell phenotypes induced by I.N. vaccine administration included enhanced polyfunctionality (combined IFN-γ and TNF expression) and greater numbers of T central memory (T CM ) cells. These phenotypes were T cell-intrinsic and could be recalled in the lungs and/or brachial LNs upon antigen challenge after adoptive T cell transfer to naïve recipients. Furthermore, mucosal vaccination induced antibody responses that were similarly effective in neutralising the binding of the parental strain of S-RBD to its ACE2 receptor, but showed greater cross-neutralising capacity against multiple variants of concern (VOC), compared to S.C. vaccination. I.N. vaccination provided significant protection from lung pathology compared to unvaccinated animals upon challenge with homologous and heterologous SARS-CoV-2 strains in a hamster model. Interpretation These results highlight the role of nasal vaccine administration in imprinting an immune profile associated with long-term T cell retention and diversified neutralising antibody responses, which could be applied to improve vaccines for COVID-19 and other infectious diseases. Funding This study was funded by Duke-NUS Medical School , the Singapore Ministry of Education , the National Medical Research Council of Singapore and a DBT-BIRAC Grant.

The delivery device of SARS-CoV-2 mucosal vaccine matters

Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants

Mucosal boosting

Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization

Protection Against SARS-CoV-2 Infection by a Mucosal Vaccine in Rhesus Macaques.

Mucosal prime-boost immunization with live murine pneumonia virus-vectored SARS-CoV-2 vaccine is protective in macaques

Mucosal SARS-CoV-2 vaccination of rodents elicits superior systemic T central memory function and cross-neutralising antibodies against variants of concern

Mucosal Vaccine Development for Respiratory Viral Infections

Sex-biased immunogenicity of a mucosal subunit vaccine against SARS-CoV-2 in mice

Mucosal vaccine delivery: A focus on the breakthrough of specific barriers

Enhanced mucosal B- and T-cell responses against SARS-CoV-2 after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant

Induction of Mucosal Immunity Through Systemic Immunization: Phantom or Reality?

Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates

Pulmonary delivery of mucosal nanovaccines

SARS-CoV-2 Mucosal Vaccine Protects Against Clinical Disease with Sex Bias in Efficacy.

Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates

An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission

The impact of vaccine type and booster dose on the magnitude and breadth of SARS-CoV-2-specific systemic and mucosal antibodies among COVID-19 vaccine recipients

Intranasal administration of unadjuvanted SARS-CoV-2 spike antigen boosts antigen-specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters

Intranasal boosting with RBD-HR protein vaccine elicits robust mucosal and systemic immune responses

An Intranasally Administrated SARS-CoV-2 Beta Variant Subunit Booster Vaccine Prevents Beta Variant Replication in Rhesus Macaques